Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma

Jean El-Cheikh, Roberto Crocchiolo, Sabine Furst, Anne Marie Stoppa, Patrick Ladaique, Catherine Faucher, Boris Calmels, Claude Lemarie, Jean Marc Schiano De Colella, Angela Granata, Diane Coso, Reda Bouabdallah, Christian Chabannon, Didier Blaise

Research output: Contribution to journalArticle

Abstract

This study examines the long-term outcomes of a cohort of patients with myeloma who were treated with reduced-intensity conditioning (RIC) regimens after a minimum follow-up of 5 years at our centre. A total of 53 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem-cell transplantation (Allo-SCT) between January 2000 and January 2007 were identified. The median follow-up of living patients was 84 months (51-141). The median age of the MM patients was 50 (28-70) years. Fifty-one patients (96%) received a transplant from a sibling donor. The median time between diagnosis and Allo-SCT was 34 months (6-161), and the median time between auto-SCT and Allo-SCT was 10 months (1-89). Fifty-one patients (96%) received at least one auto-SCT; 24 patients (45%) received a tandem auto-Allo-SCT. At last follow-up, 21 patients (40%) are alive >5 years post RIC Allo-SCT. At last follow-up, 14 (26%) are in first complete remission (CR), and four patients (8%) in second CR after donor lymphocyte infusion or re-induction with one of the new anti-myeloma drugs (bortezomib or lenalidomide) after Allo-SCT. Eight patients (38%) among these long survivors received one of these new drugs as induction or relapse treatment before Allo-SCT. Disease status and occurrence of cGvHD were significantly associated with progression-free survival (PFS); hazard ratio (HR)=0.62 (0.30-1.29, P=0.20). Acute GvHD was correlated with higher transplant-related mortality; HR=4.19 (1.05-16.77, P=0.04). No variables were associated with overall survival (OS). In conclusion, we observe that long-term disease control can be expected in a subset of MM patients undergoing RIC Allo-SCT. After 10 years, the OS and PFS were 32% and 24%, respectively. The PFS curve after Allo-SCT stabilizes in time with a plateau after 6 years post Allo-SCT.

Original languageEnglish
Pages (from-to)370-374
Number of pages5
JournalAmerican Journal of Hematology
Volume88
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Disease-Free Survival
Conditioning (Psychology)
Tissue Donors
Transplants
Survival
Pharmaceutical Preparations
Survivors
Siblings
Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. / El-Cheikh, Jean; Crocchiolo, Roberto; Furst, Sabine; Stoppa, Anne Marie; Ladaique, Patrick; Faucher, Catherine; Calmels, Boris; Lemarie, Claude; De Colella, Jean Marc Schiano; Granata, Angela; Coso, Diane; Bouabdallah, Reda; Chabannon, Christian; Blaise, Didier.

In: American Journal of Hematology, Vol. 88, No. 5, 05.2013, p. 370-374.

Research output: Contribution to journalArticle

El-Cheikh, J, Crocchiolo, R, Furst, S, Stoppa, AM, Ladaique, P, Faucher, C, Calmels, B, Lemarie, C, De Colella, JMS, Granata, A, Coso, D, Bouabdallah, R, Chabannon, C & Blaise, D 2013, 'Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma', American Journal of Hematology, vol. 88, no. 5, pp. 370-374. https://doi.org/10.1002/ajh.23412
El-Cheikh, Jean ; Crocchiolo, Roberto ; Furst, Sabine ; Stoppa, Anne Marie ; Ladaique, Patrick ; Faucher, Catherine ; Calmels, Boris ; Lemarie, Claude ; De Colella, Jean Marc Schiano ; Granata, Angela ; Coso, Diane ; Bouabdallah, Reda ; Chabannon, Christian ; Blaise, Didier. / Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. In: American Journal of Hematology. 2013 ; Vol. 88, No. 5. pp. 370-374.
@article{808242b6f5ad4575bdd0c238d4946b4c,
title = "Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma",
abstract = "This study examines the long-term outcomes of a cohort of patients with myeloma who were treated with reduced-intensity conditioning (RIC) regimens after a minimum follow-up of 5 years at our centre. A total of 53 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem-cell transplantation (Allo-SCT) between January 2000 and January 2007 were identified. The median follow-up of living patients was 84 months (51-141). The median age of the MM patients was 50 (28-70) years. Fifty-one patients (96{\%}) received a transplant from a sibling donor. The median time between diagnosis and Allo-SCT was 34 months (6-161), and the median time between auto-SCT and Allo-SCT was 10 months (1-89). Fifty-one patients (96{\%}) received at least one auto-SCT; 24 patients (45{\%}) received a tandem auto-Allo-SCT. At last follow-up, 21 patients (40{\%}) are alive >5 years post RIC Allo-SCT. At last follow-up, 14 (26{\%}) are in first complete remission (CR), and four patients (8{\%}) in second CR after donor lymphocyte infusion or re-induction with one of the new anti-myeloma drugs (bortezomib or lenalidomide) after Allo-SCT. Eight patients (38{\%}) among these long survivors received one of these new drugs as induction or relapse treatment before Allo-SCT. Disease status and occurrence of cGvHD were significantly associated with progression-free survival (PFS); hazard ratio (HR)=0.62 (0.30-1.29, P=0.20). Acute GvHD was correlated with higher transplant-related mortality; HR=4.19 (1.05-16.77, P=0.04). No variables were associated with overall survival (OS). In conclusion, we observe that long-term disease control can be expected in a subset of MM patients undergoing RIC Allo-SCT. After 10 years, the OS and PFS were 32{\%} and 24{\%}, respectively. The PFS curve after Allo-SCT stabilizes in time with a plateau after 6 years post Allo-SCT.",
author = "Jean El-Cheikh and Roberto Crocchiolo and Sabine Furst and Stoppa, {Anne Marie} and Patrick Ladaique and Catherine Faucher and Boris Calmels and Claude Lemarie and {De Colella}, {Jean Marc Schiano} and Angela Granata and Diane Coso and Reda Bouabdallah and Christian Chabannon and Didier Blaise",
year = "2013",
month = "5",
doi = "10.1002/ajh.23412",
language = "English",
volume = "88",
pages = "370--374",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma

AU - El-Cheikh, Jean

AU - Crocchiolo, Roberto

AU - Furst, Sabine

AU - Stoppa, Anne Marie

AU - Ladaique, Patrick

AU - Faucher, Catherine

AU - Calmels, Boris

AU - Lemarie, Claude

AU - De Colella, Jean Marc Schiano

AU - Granata, Angela

AU - Coso, Diane

AU - Bouabdallah, Reda

AU - Chabannon, Christian

AU - Blaise, Didier

PY - 2013/5

Y1 - 2013/5

N2 - This study examines the long-term outcomes of a cohort of patients with myeloma who were treated with reduced-intensity conditioning (RIC) regimens after a minimum follow-up of 5 years at our centre. A total of 53 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem-cell transplantation (Allo-SCT) between January 2000 and January 2007 were identified. The median follow-up of living patients was 84 months (51-141). The median age of the MM patients was 50 (28-70) years. Fifty-one patients (96%) received a transplant from a sibling donor. The median time between diagnosis and Allo-SCT was 34 months (6-161), and the median time between auto-SCT and Allo-SCT was 10 months (1-89). Fifty-one patients (96%) received at least one auto-SCT; 24 patients (45%) received a tandem auto-Allo-SCT. At last follow-up, 21 patients (40%) are alive >5 years post RIC Allo-SCT. At last follow-up, 14 (26%) are in first complete remission (CR), and four patients (8%) in second CR after donor lymphocyte infusion or re-induction with one of the new anti-myeloma drugs (bortezomib or lenalidomide) after Allo-SCT. Eight patients (38%) among these long survivors received one of these new drugs as induction or relapse treatment before Allo-SCT. Disease status and occurrence of cGvHD were significantly associated with progression-free survival (PFS); hazard ratio (HR)=0.62 (0.30-1.29, P=0.20). Acute GvHD was correlated with higher transplant-related mortality; HR=4.19 (1.05-16.77, P=0.04). No variables were associated with overall survival (OS). In conclusion, we observe that long-term disease control can be expected in a subset of MM patients undergoing RIC Allo-SCT. After 10 years, the OS and PFS were 32% and 24%, respectively. The PFS curve after Allo-SCT stabilizes in time with a plateau after 6 years post Allo-SCT.

AB - This study examines the long-term outcomes of a cohort of patients with myeloma who were treated with reduced-intensity conditioning (RIC) regimens after a minimum follow-up of 5 years at our centre. A total of 53 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem-cell transplantation (Allo-SCT) between January 2000 and January 2007 were identified. The median follow-up of living patients was 84 months (51-141). The median age of the MM patients was 50 (28-70) years. Fifty-one patients (96%) received a transplant from a sibling donor. The median time between diagnosis and Allo-SCT was 34 months (6-161), and the median time between auto-SCT and Allo-SCT was 10 months (1-89). Fifty-one patients (96%) received at least one auto-SCT; 24 patients (45%) received a tandem auto-Allo-SCT. At last follow-up, 21 patients (40%) are alive >5 years post RIC Allo-SCT. At last follow-up, 14 (26%) are in first complete remission (CR), and four patients (8%) in second CR after donor lymphocyte infusion or re-induction with one of the new anti-myeloma drugs (bortezomib or lenalidomide) after Allo-SCT. Eight patients (38%) among these long survivors received one of these new drugs as induction or relapse treatment before Allo-SCT. Disease status and occurrence of cGvHD were significantly associated with progression-free survival (PFS); hazard ratio (HR)=0.62 (0.30-1.29, P=0.20). Acute GvHD was correlated with higher transplant-related mortality; HR=4.19 (1.05-16.77, P=0.04). No variables were associated with overall survival (OS). In conclusion, we observe that long-term disease control can be expected in a subset of MM patients undergoing RIC Allo-SCT. After 10 years, the OS and PFS were 32% and 24%, respectively. The PFS curve after Allo-SCT stabilizes in time with a plateau after 6 years post Allo-SCT.

UR - http://www.scopus.com/inward/record.url?scp=84876718764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876718764&partnerID=8YFLogxK

U2 - 10.1002/ajh.23412

DO - 10.1002/ajh.23412

M3 - Article

C2 - 23460414

AN - SCOPUS:84876718764

VL - 88

SP - 370

EP - 374

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 5

ER -